Washington, DC, July 06, 2023 (GLOBE NEWSWIRE) — Patient advocacy organization UsAgainstAlzheimer’s today hailed the first-of-its-kind traditional approval by the Food and Drug Administration (FDA) of lecanemab (marketed as Leqembi), a treatment for early-stage Alzheimer’s. This historic development brings a treatment option and renewed hope for continued innovation to the…Read More
UsAgainstAlzheimers Applauds FDA Approval of Leqembi for Treatment of EarlyStage Alzheimers
